1. Home
  2. SKYE vs WHF Comparison

SKYE vs WHF Comparison

Compare SKYE & WHF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$1.78

Market Cap

9.0M

Sector

Health Care

ML Signal

HOLD

Logo WhiteHorse Finance Inc.

WHF

WhiteHorse Finance Inc.

HOLD

Current Price

$7.08

Market Cap

152.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SKYE
WHF
Founded
2012
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
9.0M
152.5M
IPO Year
2013
2012

Fundamental Metrics

Financial Performance
Metric
SKYE
WHF
Price
$1.78
$7.08
Analyst Decision
Strong Buy
Sell
Analyst Count
3
2
Target Price
$15.00
$7.75
AVG Volume (30 Days)
81.7K
78.7K
Earning Date
05-08-2026
05-07-2026
Dividend Yield
N/A
13.67%
EPS Growth
N/A
31.91
EPS
N/A
0.44
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$16.76
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$6.07
52 Week High
$4.99
$7.87

Technical Indicators

Market Signals
Indicator
SKYE
WHF
Relative Strength Index (RSI) 54.89 50.64
Support Level $1.64 $7.08
Resistance Level $2.28 $7.22
Average True Range (ATR) 0.22 0.18
MACD -0.07 0.00
Stochastic Oscillator 32.00 25.61

Price Performance

Historical Comparison
SKYE
WHF

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

About WHF WhiteHorse Finance Inc.

WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.

Share on Social Networks: